摘要
目的:探讨了恶性葡萄胎患者化疗前后血浆leptin、ET-1和血清INH水平变化及临床意义。方法:分别应用放射免疫分析和酶联法对31例恶性葡萄胎患者进行了化疗前后血浆leptin、ET-1和血清INH测定,并与35例正常健康人做比较。结果:恶性葡萄胎患者在化疗前血浆leptin、ET-1和血清INH水平变化均非常显著地高于正常人组(P<0.01),化疗后6个月与正常人组比较仍有差异(P<0.05)。结论:恶性葡萄胎患者是一种可呈现自身免疫异常和免疫调节障碍的疾病。
Objective To explore the clinical significance of changes of plasma leptin,ET-1 and serum INH levels after chematherapy in patients with malignant hydatidiform mole.Methods Plasma leptin ET-1（with RIA） serum INH（with ELISA） levels were measured both before and after chemotherapy in 31 patients with malignant hydatidiform mole as well as in 35 controls.Results Before chemotherapy plasma leptin,ET-1 and serum INH levels were remarkably higher in the patients than those in controls（P0.01）,six months after chemotherapy,the levels changed marked by toward normal,but remained significantly different from those in controls（P0.05）.Conclusion Abnormal autoimmune and immuno-regulation disorder were present in patients with malignant hydatidiform mole.
出处
《放射免疫学杂志》
CAS
2011年第3期263-264,共2页
Journal of Radioimmanology
关键词
恶性葡萄胎
瘦素
内皮素
抑制素
malignant hydatidiform mole
leptin
endothelin-1（ET-1）
inhibim（INH）
